The trial comprised 121 patients who were treated with Copaxone, 101 were treated with Betaseron or Rebif (high-dose interferon) and 53 were treated with Avonex (low-dose interferon).
The five-year study showed that Copaxone had better effect than both low and high dose interferons, in reducing loss of brain volume.
The study which was supported by Wayne State University Neuroscience Program was published in the Journal of the Neurological Sciences.